| $BIXT's recent performance is characterized by a remarkable 6.24% increase in its trading price, reaching $0.16, along with a trading volume of 72.97K, |
| @henryfordly |
10/27/2023 3:21:27 PM |
| The USPTO's publication of $BIXT's patent signifies its commitment to advancing healthcare. Reflecting in their market cap of $21.7M+ and a bullish trading |
| @traderquine |
10/27/2023 1:36:47 PM |
| Explore $BIXT's dedication to healthcare transformation. Their mission is clear: develop and commercialize solutions for critical medical challenges. With 144 |
| @alicenoble32 |
10/27/2023 8:01:05 AM |
| Bioxytran, Inc. ( $BIXT) on their journey to improve healthcare. Their 144 million outstanding shares and a trading price of $0.16245 reflect their unique and |
| @alicenoble32 |
10/26/2023 1:31:16 PM |
| Bioxytran, Inc. ($BIXT) is making waves in antiviral research. Their patent application signals significant progress, while a market cap exceeding $23M speaks |
| @traderquine |
10/26/2023 10:52:34 AM |
| Witness Bioxytran, Inc. ($BIXT) as they relentlessly pursue transformative medical solutions, demonstrated in their robust market performance. With a market |
| @alicenoble32 |
10/25/2023 2:55:08 PM |
| Bioxytran, Inc. ($BIXT) is revolutionizing healthcare with an unwavering commitment to addressing unmet medical needs. From inflammation to cancer, they're |
| @traderquine |
10/25/2023 8:12:21 AM |
| With 144.35 million outstanding shares and a brisk 30-day average volume of 152.694, $BIXT leads the biotechnology field. Their previous closing price of $0. |
| @alicenoble32 |
10/24/2023 2:47:12 PM |
| The mission of Bioxytran, Inc. is to provide better patient care. Their ongoing research efforts, which target diseases ranging from inflammation to stroke, |
| @traderquine |
10/24/2023 11:59:56 AM |
| Witness the remarkable strength of $BIXT in the biotech realm, as they command a market cap exceeding $24.5 million, 144 million+ outstanding shares, and a |
| @alicenoble32 |
10/20/2023 10:14:16 AM |
| The $BIXT's 30-day average trading volume of 161K+ emphasizes the consistent interest and confidence investors have in Bioxytran's initiatives. The robust |
| @traderquine |
10/20/2023 8:00:37 AM |
| Explore the profound influence of $BIXT in biotech, driven by their strong market presence and a mission to address critical medical challenges. additionally |
| @alicenoble32 |
10/19/2023 11:42:22 AM |
| Bioxytran, Inc. ($BIXT) moves gracefully through the biopharmaceutical industry. 144.35 million+ outstanding shares show a significant presence. They are |
| @traderquine |
10/19/2023 7:45:02 AM |
| Bioxytran, Inc. ($BIXT) is a clinical-stage pharmaceutical company pioneering advanced therapies to combat hypoxia in humans. With a remarkable market cap of |
| @traderquine |
10/18/2023 8:43:24 AM |
| Discover the future of patient care and global health with Bioxytran, Inc. ($BIXT). Their unwavering focus on medical innovation positions them as a leader in |
| @alicenoble32 |
10/17/2023 1:54:04 PM |
| Bioxytran, Inc.'s steadfast approach towards tackling inflammation and cancer, especially with Prolectin-M, coupled with a robust market cap of $20.9M+, |
| @traderquine |
10/17/2023 10:08:37 AM |
| Bioxytran, Inc.($BIXT) continues to gain momentum in the biopharmaceutical sector with a substantial market cap of $24.5M+. Their focus on Glycovirology, |
| @traderquine |
10/16/2023 10:08:28 AM |
| Bioxytran, Inc.($BIXT) is committed to medical progress through biotechnology. ProLectin-M and ProLectin-I are poised to make a difference in Covid-19, |
| @alicenoble32 |
10/16/2023 7:12:09 AM |
| Bioxytran, Inc. sets trends in the biopharma industry rather than merely participating in it. Their commitment to developing novel drug designs and a healthy |
| @traderquine |
10/13/2023 7:51:44 AM |
| $BIXT's trading volume, averaging 200.94K shares over the last 30 days, demonstrates its strong presence and attractiveness to investors interested in growth |
| @henryfordly |
10/12/2023 11:51:06 AM |
| Dive into the world of biotechnology with Bioxytran, Inc. ($BIXT). Their drug candidates, ProLectin-M and ProLectin-I, are set to make a difference in Covid- |
| @alicenoble32 |
10/11/2023 3:05:31 PM |
| As Bioxytran, Inc. ($BIXT) delves into specialized fields like Glycovirology and combats degenerative diseases, its market statistics reflect its growing |
| @traderquine |
10/11/2023 8:26:53 AM |
| $BIXT is reshaping the clinical-stage pharma landscape. With shares at $0.176 and a market cap of $26.32M, they're harnessing Galectin inhibitors for |
| @alicenoble32 |
10/10/2023 3:34:04 PM |
| As a clinical-stage pharmaceutical company, Bioxytran ($BIXT) has shown promise by developing platform technologies that address critical health challenges. |
| @traderquine |
10/10/2023 7:17:18 AM |
| Bioxytran, Inc. ($BIXT), where innovation in research and development is the driving force. Their vision to conquer critical medical challenges is backed by a |
| @alicenoble32 |
10/09/2023 12:01:47 PM |
| $BIXT's groundbreaking work in oxygen therapeutic treatments is reflected in its market cap of $26.45 million, a testament to its potential in the healthcare |
| @henryfordly |
10/09/2023 10:13:41 AM |
| Bioxytran, Inc.'s ($BIXT) performance in the market reflects their potential and investor interest. With a market capitalization exceeding $26.4 million and a |
| @traderquine |
10/09/2023 8:28:00 AM |
| $BIXT.'s primary drug candidate, Prolectin-M, represents a groundbreaking approach to antiviral therapy. It is designed to target galectins, which play a |
| @henryfordly |
09/21/2023 10:53:45 AM |
| Bioxytran, Inc.'s primary drug candidate, Prolectin-M, represents a groundbreaking approach to antiviral therapy. It is designed to target galectins, which |
| @henryfordly |
09/21/2023 10:52:46 AM |
| Bioxytran, Inc. ($BIXT) is taking the fight against COVID-19 to new heights with ProLectin-M. Achieving a 100% negative PCR test rate by day 7 is a remarkable |
| @Olivia777 |
09/21/2023 10:27:09 AM |
| As an active participant in the OTC market, $BIXT's trading at $0.201 with a 3.08% increase in price is indicative of the increasing interest in its |
| @henryfordly |
09/20/2023 9:19:14 AM |
| Finally, Bioxytran, Inc. is clearly building a name for itself in the worlds of biotechnology and healthcare innovation. Their dedication to discovering |
| @steffanhen570 |
09/20/2023 8:06:58 AM |
| $BIXT's recent 23.29% price surge underscores its market resilience and the strong demand for its solutions. This surge signifies a growing investor belief in |
| @henryfordly |
09/19/2023 12:29:53 AM |
| In a world where the intersection of science, technology, and healthcare is constantly evolving, Bioxytran, Inc. ($BIXT) stands out as a company that not only |
| @steffanhen570 |
09/18/2023 11:24:56 PM |
| $BIXT's focus on oxygen therapeutic treatments addresses a critical medical need, especially in cases of hypoxia. This focus on enhancing patient care and |
| @henryfordly |
09/15/2023 12:07:19 AM |
| Bioxytran, Inc. ($BIXT) is on a mission that goes beyond traditional medical research. They are revolutionizing the treatment landscape by pioneering novel |
| @steffanhen570 |
09/14/2023 10:22:02 PM |
| As an active participant in the OTC market, $BIXT's trading volume of 136.32K is indicative of the increasing interest in its pioneering approach to oxygen |
| @henryfordly |
09/14/2023 2:11:23 AM |
| The surge in trading volume for $BIXT highlights the increasing interest and confidence in its innovative medical advancements. Investors are recognizing the |
| @henryfordly |
09/13/2023 2:10:10 AM |
| One of the medical concerns Bioxytran, Inc. is addressing is hypoxia, a condition characterised by low oxygen levels in the body. Their novel ideas have the |
| @steffanhen570 |
09/12/2023 9:22:48 PM |
| Hypoxia, a condition characterized by insufficient oxygen levels in the body, is just one of the medical challenges Bioxytran, Inc. is addressing. Their |
| @steffanhen570 |
09/11/2023 10:17:02 PM |
| $BIXT's standout performance on the OTC market is catching the attention of market participants, making it an exciting choice for those seeking penny stock |
| @henryfordly |
09/10/2023 10:23:48 PM |
| Within the sphere of biotechnology, Bioxytran, Inc.($BIXT) stands as a trailblazer, committed to the creation of innovative therapies targeting significant |
| @Olivia777 |
09/10/2023 9:13:05 PM |
| $BIXT's market capitalization of $24.42 million on the OTC market reflects its financial stability and growth potential. Investors are increasingly drawn to |
| @henryfordly |
09/07/2023 10:28:44 PM |
| With a substantial share count, Bioxytran, Inc. ($BIXT) is undeniably having a game-changing impact. Their unwavering focus on innovation is shifting the |
| @Olivia777 |
09/07/2023 9:17:08 PM |
| $BIXT is currently trading at $0.19 per share, reflecting a notable increase in price. This spike in price indicates heightened market interest and optimism |
| @henryfordly |
09/06/2023 10:20:51 PM |
| Bioxytran, Inc. ($BIXT) stands as a pillar of hope against hypoxia, driven by its unwavering pursuit of clinical-stage treatments. On the OTC market, as a |
| @Olivia777 |
09/06/2023 8:03:19 PM |
| Penny stocks can be a fascinating arena for investors, offering the allure of substantial growth. $BIXT is one such penny stock that's catching the attention |
| @steffanhen570 |
09/06/2023 7:59:25 PM |
| Bioxytran Inc. ($BIXT) is a leader in the fields of glycovirology, hypoxia, and degenerative diseases and provides cutting-edge solutions that have the |
| @Olivia777 |
09/05/2023 8:33:38 PM |
| For investors seeking opportunities in the OTC market, $BIXT's position is worth noting. It represents the possibility of significant returns and a chance to |
| @steffanhen570 |
09/04/2023 8:11:21 PM |
| With a market cap that signals promise, $BIXT is charting a course for growth. The company's dedication to innovation and its commitment to addressing unmet |
| @steffanhen570 |
09/03/2023 7:33:11 PM |
| Bioxytran, Inc. ($BIXT)'s commitment to providing safe and effective treatments for patients suffering from viral infections and hypoxia is admirable. Hypoxia |
| @steffanhen570 |
08/31/2023 9:21:27 PM |
| ProLectin-M Enters Clinical Phase, Marking Bioxytran's ($BIXT) Triumph Eagerly anticipated galectin inhibitor holds potential against COVID-19. The stock has |
| @roj82223 |
08/30/2023 11:40:27 AM |
| Prepare to witness the transformation of healthcare with Bioxytran, Inc. ($BIXT) leading the way. At the forefront of clinical-stage innovations, this |
| @steffanhen570 |
08/30/2023 11:35:21 AM |
| Biotech with Bioxytran, Inc. ($BIXT)! Their clinical-stage therapies are targeting unmet medical needs in virology, degenerative diseases, and hypoxia. With a |
| @bellaria876 |
05/04/2023 8:32:50 AM |
| $BIXT Bioxytran, Inc. is a pharmaceutical company that specialises in developing efficient therapies for human hypoxia. 123 Million shares of this stock are |
| @bellaria876 |
05/03/2023 7:47:31 AM |
| nayiralee: BIOXYTR |
| @Lsbtc |
05/02/2023 7:06:51 PM |
| The dedication of Bioxytran, Inc. ($BIXT) to providing safe and effective treatments for people suffering from viral illnesses and hypoxia is wonderful to see |
| @bellaria876 |
05/02/2023 12:26:09 PM |
| $BIXT's return to the OTC market marks a significant turning point for the company and the industry. With shares trading at 0.4814 and significant volume, $ |
| @anthonysolle123 |
05/02/2023 11:27:05 AM |
| $BIXT #MarketWatch "Bioxytran Interview at the Emerging |
| @deej42 |
05/01/2023 3:38:44 PM |
| $BIXT News! Bioxytran Interview at the Emerging Growth Conference |
| @Prudence79 |
05/01/2023 2:10:24 PM |
| nayiralee: Due to its huge market cap and superior biotechnology service, $BIXT has been attracting inve |
| @mrnomad101 |
05/01/2023 12:12:40 PM |
| A biotechnology company called Bioxytran, Inc.($BIXT) is in the clinical stages of developing novel therapies with the goal of meeting unmet medical needs in |
| @bellaria876 |
05/01/2023 7:01:16 AM |
| $BIXT going to bff egg on twitter in |
| @Bryanb48 |
04/21/2023 5:08:20 PM |
| agreed |
| @electtrader1 |
04/19/2023 1:44:06 PM |
| Yes.
This was the reason I first bought |
| @SeleneS |
04/19/2023 1:43:30 PM |
| news Bioxytran Tests Acellular Oxygen Carrier BXT-25 in |
| @Floridamike55 |
04/19/2023 1:15:43 PM |
| Agreed |
| @mmm |
04/18/2023 11:53:45 AM |
| Yes. Im hearing reports of a new |
| @Mattyhudz20 |
04/18/2023 11:35:40 AM |
| https://www.zerohedge.com/news/2023-04-12/white-house-blow-5-billion-project-nex |
| @raswantie |
04/14/2023 7:32:15 PM |
| https://twitter.com/MikeSheikh2/status/1646418064236511233?s=20 |
| @garrettdeasy |
04/14/2023 2:11:46 PM |
| $BIXT filed annual report! |
| @sents14 |
04/01/2023 4:59:26 AM |
| This is excellent news of a peer reviewed |
| @jeffjones |
03/29/2023 4:55:40 PM |
| So now Sir, what are your thoughts on |
| @TomS |
03/29/2023 4:54:51 PM |
| Some nice news out this morning |
| @mvpvail1 |
03/29/2023 12:59:53 PM |
| NEWS: Bioxytran Announces Positive Phase 2 Trial Results |
| @mkelemen |
03/29/2023 11:57:39 AM |
| How can you possibly say that when 88% |
| @Bucca316 |
03/29/2023 2:40:17 AM |
| https://microcapdaily.com/bioxytran-otcmkts-bixt-peer-review-published-showing-f |
| @Bjohnson704 |
03/29/2023 2:38:13 AM |
| No Problem......just calling it like I see it.......and |
| @swisstpa |
03/28/2023 8:17:21 PM |
| Not what the charts showed...... |
| @bulpen |
03/28/2023 8:16:30 PM |
| What is your problem?
Do you not remember that |
| @Rkd2412 |
03/28/2023 3:14:23 PM |
| Are you drunk or on drugs?
88% were symptom-free |
| @wmsanders1 |
03/28/2023 3:12:52 PM |
| Activity in Influenza and Respiratory Syncytial Virus highlights |
| @Orion |
03/28/2023 2:26:36 PM |
| On 11-16-22, $BIXT added 5M to the Float |
| @cap |
03/28/2023 9:23:27 AM |
| You know what's worse than somebody saying No |
| @Gajravyas |
03/28/2023 9:16:03 AM |
| How many years has it been now. I |
| @Dtang |
03/28/2023 9:14:27 AM |
| Seems like that clinical trial didn't work....some charts |
| @JohnVonDenver |
03/28/2023 9:02:55 AM |
| Yawwwwnnnnnn..................... |
| @Initfortheride |
03/28/2023 9:01:20 AM |
| I think that actually makes it worse.........lol......... |
| @Sirius |
03/28/2023 9:00:23 AM |
| Amazing news on $BIXT!
https://www.zerohedge.com/news/2023-03-07/sick-jabs-and |
| @AlienSe7en |
03/28/2023 3:27:38 AM |
| https://www.mdpi.com/2076-393X/11/4/731 |
| @Bbbbrad55 |
03/28/2023 3:25:16 AM |
| https://twitter.com/EnemyInAState/status/1640129869106368517 |
| @DT2591 |
03/28/2023 3:24:19 AM |
| Watch About BioxyTran Inc, Emerging Growth Highlights Reel |
| @bnatraj |
03/27/2023 5:28:43 PM |
| $BIXT Has big news update coming.. stay tuned!! |
| @Jellis333 |
03/27/2023 1:35:52 PM |
| Its going to take time and money to |
| @BeethovenL |
03/21/2023 11:17:18 AM |
| The importance is in the cure--not the pump |
| @JamieLee |
03/17/2023 8:15:56 PM |
| I think investors like ourselves should be posting |
| @kanavale |
03/14/2023 5:44:17 PM |
| Nice article...............Z |
| @jg935 |
03/14/2023 5:26:22 PM |
| This is looking great |
| @MJR4826 |
03/14/2023 1:36:56 PM |
| https://insiderfinancial.com/bixt-spikes-on-delayed-reaction-to-the-most-powerfu |
| @po5134 |
03/14/2023 5:03:10 AM |
| $BIXT 32X AVERAGE VOLUME....people are catching on to |
| @Alpert |
03/08/2023 7:37:34 PM |
| IMO, $BIXT will be the next Moderna, not |
| @ohmyhemp |
03/08/2023 6:33:12 PM |
| running nicely on article out very thin https://www.zerohedge.com/news/2023-03-0 |
| @mypenneys |
03/08/2023 4:26:05 PM |
| New article out on Zerohedge highlighting ProLectin. Drug |
| @drrak |
03/08/2023 3:51:20 PM |
| No doubt. Why waste $$ on fake pumper |
| @Jalapenohiway |
03/07/2023 7:51:28 PM |
| Like all biotech companies, it takes lots of |
| @Everett |
03/04/2023 5:06:15 PM |
| They have M Sheikh as a "executive"?? |
| @RESPREE |
03/03/2023 5:31:58 AM |
| Bioxytran $BIXT:
Yesterday announced a significant drop in viral |
| @psalling |
03/01/2023 3:55:06 PM |
| And, can't sell this POS either! |
| @gemshell1 |
03/01/2023 3:32:52 PM |
| Market yawned. No one believes the PRs they |
| @knadre14 |
03/01/2023 2:18:23 AM |
| Bioxytran $Bixt
Activity in Influenza and |
| @Bprojects |
02/28/2023 1:57:07 PM |
| misiu143: Informative interview on Proactive. https://www.proactiveinvestors.com/companies/news/1005615/bio |
| @p3healthcare |
02/10/2023 5:09:25 PM |
| AviseAnalytics: AVISE ANALYTICS REINITIATES COVERAGE ON BIOXYTRAN INC. $BIXT We reinitiate our |
| @AviseAnalytics |
11/22/2022 6:28:20 PM |
| jk1550: Can someone please tell us what is going on with this company and its management? It appears their s |
| @jordan |
11/16/2020 7:03:19 PM |
| Kevin0461: What happened to BIXT??? |
| @jack047 |
04/21/2020 4:35:48 PM |
| jedijazz: $BIXT NEWS ~ BIOXYTRANS MDX VIEWER DEMONSTRATES EARLY WARNING SIGNS OF BRAIN HEALTH DURIN |
| @greenor |
06/06/2019 1:29:15 PM |
| jmtimz: $BIXT 80% Buy with a Average short term outlook on maintaining the current direction. https://w |
| @Hilton |
05/31/2019 2:33:13 PM |
| Lee Adams: Bioxytran Inc. Announces Availability of Updated Investor Presentation BOSTON, MASSACHUSET |
| @robertbuffet |
05/29/2019 5:50:13 PM |
| jedijazz: $BIXT $1.34 +5.51% on NEWS: Bioxytran Inc. Announces Availability of Updated Investor Presentation h |
| @erictili11 |
05/29/2019 2:59:21 PM |
| jedijazz: $BIXT Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure ti |
| @apple5555 |
05/28/2019 3:27:32 PM |
| jedijazz: $BIXT @bioxytran Overall Average: 72% BUY @Barchart https://www.barchart.com/stocks/quotes/bixt/op |
| @jtwhln |
05/24/2019 2:40:16 PM |
| jedijazz: $BIXT Bioxytran Inc In Today's News & Barchart Buy Opinion is 64% with a Average short ter |
| @parkkisam |
05/20/2019 5:24:56 PM |
| jedijazz: $BIXT News: Bioxytran Using Paradigm Changing Vital Sign that Can Measure Real Time Tissue |
| @rhoffman |
05/20/2019 12:05:01 PM |
| jedijazz: $BIXT new HOD @ $1.35 +35.00% Bioxytran Inc Today's Higher Barchart Buy Opinion is 64% with a Averag |
| @loansolutions1234 |
05/15/2019 6:35:55 PM |
| jedijazz: $BIXT Bioxytran Inc @Barchart Overall 56% Buy Opinion with a Average short term outlook on maintaini |
| @Sojourner |
05/14/2019 6:24:10 PM |
| jedijazz: $BIXT Interesting Video: Rising Problems & Innovations in the Treatment of Stroke - |
| @Cgold |
05/10/2019 4:43:58 PM |
| jedijazz: $BIXT Rising Problems & Innovations in the Treatment of Stroke - http |
| @elonstonks |
05/08/2019 2:25:20 PM |
| jedijazz: $BIXT Bioxytran, Inc. is a BioPharma company whose mission is to develop drug to treat stroke |
| @arz |
05/07/2019 2:06:25 PM |
| jedijazz: $BIXT Buy Opinion https://www.barchart.com/stocks/quotes/BIXT/opinion |
| @nthyaga |
05/06/2019 1:15:10 PM |
| jedijazz: $BIXT NEWS: Bioxytran Inc. Announces Appointment of Ex Bristol-Myers Squibb Executive to S |
| @sarandev |
05/06/2019 1:03:19 PM |
| jedijazz: $BIXT Bioxytrans New interview with proactive investors http://ow.ly/GRRf50tWICm |
| @TexasTrades |
05/03/2019 5:57:37 PM |
| jedijazz: $BIXT Bioxytran #Biotech that saves lives as $BIXT's molecule BXT-25 will transport oxygen |
| @Slappya45 |
04/30/2019 7:12:33 PM |
| Lee Adams: BIXT : BXT-25 CAN BIOXYTRAN INCS NOVEL DRUG REVOLUTIONIZE OXYGEN DELIVERY? http://www.avi |
| @arbo99 |
04/30/2019 1:41:11 PM |
| jedijazz: $BIXT Treatment of Stroke- https://youtu.be/i5iCUIjtVcM via @YouTube @frontpagestock |
| @Raiders1 |
04/30/2019 12:55:26 PM |
| jedijazz: Time is literally brain tissue. The longer patients wait before the flow of oxygen to impacted are |
| @jbarry |
04/30/2019 12:55:12 PM |
| jedijazz: $BIXT BioXyTran (OTCPK: BIXT) 5 PROMISING STOCKS IN THE STROKE MANAGEMENT INDUSTRY |
| @Richard |
04/29/2019 1:14:54 PM |
| jedijazz: $BIXT Rising Problems & Innovations in the Treatment of Stroke - http |
| @IDK55 |
04/29/2019 12:58:14 PM |
| jedijazz: $BIXT Bioxytran Inc. Licensing FDA Approved Technology from MDX Lifesciences for use in Pi |
| @GreatJobThanks |
04/26/2019 5:41:56 PM |
| jedijazz: $BIXT Bioxytran Inc. is a developmental stage biotechnology company. The company is workin |
| @Notsokojan |
04/08/2019 5:52:39 PM |
| jedijazz: $BIXT Bioxytran announces plans to use a revolutionary new device, the MDX Viewer, to meas |
| @pennytripper |
04/08/2019 1:04:28 PM |
| stocksonhighalert: $BIXT Bioxytran Licensing FDA Approved Technology from MDX Lifesciences for use in Pipeline Drug Dev |
| @JOHNB214 |
04/08/2019 11:09:37 AM |
| stocksonhighalert: BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis |
| @PENDAKE1 |
04/05/2019 5:35:02 PM |
| stocksonhighalert: Bioxytrans proprietary molecule is BXT-25 and it is designed to transport oxygen through severely b |
| @dangeline9 |
04/05/2019 5:34:47 PM |
| stocksonhighalert: About Bioxytran, Inc. Bioxytran Inc. is a developmental stage biotechnology company. The company |
| @salmanaziz |
04/05/2019 5:34:34 PM |
| stocksonhighalert: Bioxytran Licensing FDA Approved Technology from MDX Lifesciences for use in Pipeline Drug Developme |
| @universe |
04/05/2019 5:34:15 PM |
| jedijazz: Bioxytran Inc. (BIXT) 0.3800 +0.0300 (+8.57%) Bioxytran Inc. (BIXT) Amongst Todays Volume Leader h |
| @domer10 |
04/01/2019 7:05:51 PM |
| russkitrader2018: $BIXT let's see if she can close strong to end the week! News March 18 Bioxytran, Inc. Engages Re |
| @dianegracely |
03/22/2019 11:21:44 AM |
| russkitrader2018: $BIXT News... Bioxytran, Inc. Engages Resources Unlimited NW, LLC. for Strategic Investor Relations |
| @Yournewmotor |
03/19/2019 1:05:58 PM |
| jedijazz: $BIXT BOSTON, MASSACHUSETTS, March 18, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a devel |
| @MariaRHoward |
03/18/2019 2:14:32 PM |
| Lee Adams: Bioxytran, Inc. Engages Resources Unlimited NW, LLC. for Strategic Investor Relations BOST |
| @john820 |
03/18/2019 1:48:27 PM |
| Lee Adams: Bioxytran, Inc. Pioneers First Emergency Stroke Treatment Newly Developed Molecule Potentially A |
| @Kufie_Smack |
03/14/2019 4:55:27 PM |
| PoemStone: $USMN staging $0.05 OTC Website ul |
| @GH12 |
01/02/2018 3:41:56 PM |
| Emylers: USMN Financials 07/16/2014 00:52:00 U.S. Rare Earth Minerals, Inc. Period Ending Dec 31, 2013 Dec |
| @michaeljacobs |
07/16/2014 5:51:57 AM |
| Stock_Tracker: Latest U.S. Natural Nutrients and Minerals Inc. (USMN) Headlines U.S. Rare Earth Minerals |
| @Cherryblossom1234 |
03/12/2014 4:00:32 AM |
| chartguy89: USMN 0.028 Stock Charts $USMN 1 Month Chart |
| @jameshebrew |
03/10/2014 4:16:16 PM |
| chartguy89: USMN Stock Charts Last: -0.0004 Sunday, March 2, 2014 at 5:43:36 AM $USMN 1 Mont |
| @organichempmexico |
03/02/2014 10:43:47 AM |
| stocklolo: Earth's Art in Bed, OR in Tumalo: Now carries Excelerite Ag, Livestock and Fish & Pond. |
| @Stockman |
10/23/2012 12:46:49 PM |
| TrishaSwift: Stock gained 275% since 13th of august. just a matter of time before it hits the .20's range IMO! Co |
| @comcast |
09/07/2012 3:32:31 PM |
| TrishaSwift: USMN (U.S. Rare Earth Minerals) Disclaimer: Information regarding the company are based from yaho |
| @StockonHighAlert |
09/07/2012 3:06:21 PM |